MDT

81.74

-1.59%↓

VEEV

209.29

-2.32%↓

A

98.9

-4.01%↓

HQY

76.28

-4.98%↓

PDCO

31.05

+0.49%↑

MDT

81.74

-1.59%↓

VEEV

209.29

-2.32%↓

A

98.9

-4.01%↓

HQY

76.28

-4.98%↓

PDCO

31.05

+0.49%↑

MDT

81.74

-1.59%↓

VEEV

209.29

-2.32%↓

A

98.9

-4.01%↓

HQY

76.28

-4.98%↓

PDCO

31.05

+0.49%↑

MDT

81.74

-1.59%↓

VEEV

209.29

-2.32%↓

A

98.9

-4.01%↓

HQY

76.28

-4.98%↓

PDCO

31.05

+0.49%↑

MDT

81.74

-1.59%↓

VEEV

209.29

-2.32%↓

A

98.9

-4.01%↓

HQY

76.28

-4.98%↓

PDCO

31.05

+0.49%↑

Search

Innoviva Inc

Open

SectorHealthcare

17.17 -0.75

Overview

Share price change

24h

Current

Min

16.87

Max

17.76

Key metrics

By Trading Economics

Income

19M

20M

Sales

2.3M

92M

P/E

Sector Avg

50.361

63.778

EPS

0.26

Profit margin

22.147

Employees

127

EBITDA

17M

36M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+214.11% upside

Dividends

By Dow Jones

Next Earnings

6 maj 2025

Market Stats

By TradingEconomics

Market Cap

7.6M

1.1B

Previous open

17.92

Previous close

17.17

News Sentiment

By Acuity

72%

28%

359 / 386 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Bearish Evidence

Innoviva Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

7 kwi 2025, 23:56 UTC

Top News

Australian Consumer Confidence Firms Despite Market Falls

7 kwi 2025, 23:45 UTC

Hot Stocks

Stocks to Watch: CVS Health, UnitedHealth Group, Spire Global, Pacira BioSciences

7 kwi 2025, 21:36 UTC

Major Market Movers

Medicare Insurer Shares Rise on Plans for Higher Payment Rates

7 kwi 2025, 21:11 UTC

Major Market Movers

Broadcom Authorizes $10 Billion Share Repurchase Program

7 kwi 2025, 23:48 UTC

Market Talk

Nikkei May Rise After Recent Selloffs -- Market Talk

7 kwi 2025, 23:47 UTC

Market Talk

Gold Edges Lower Amid More Cautious Near-Term Outlook -- Market Talk

7 kwi 2025, 23:34 UTC

Top News

Apple Users Rush to Upgrade iPhones Ahead of Potential Tariffs-Related Price Hikes -- WSJ

7 kwi 2025, 22:18 UTC

Top News

Health Insurer Stocks Jump After Medicare Boosts Payment Rates -- Barrons.com

7 kwi 2025, 22:04 UTC

Top News

Trump Turns Screws on China, Leaves Door Open to Deals With Other Countries -- WSJ

7 kwi 2025, 21:43 UTC

Market Talk

Oil Producers Choosing Returns Over Growth In Tariffs Fallout -- Market Talk

7 kwi 2025, 21:37 UTC

Market Talk

Canada Faces Financial Crisis-Like Symptoms That Rate Cuts Won't Cure -- Market Talk

7 kwi 2025, 21:32 UTC

Acquisitions, Mergers, Takeovers

Infineon: All-Cash Transaction to Be Financed From Existing Liquidity and Additional Debt >IFX.FF

7 kwi 2025, 21:32 UTC

Acquisitions, Mergers, Takeovers

Infineon: Transaction Combines Infineon's Portfolio for Automotive Microcontrollers With Automotive Ethernet Business of Marvell, Accelerating Infineon's System Capabilities for Software-Defined Vehicles >IFX.FF

7 kwi 2025, 21:32 UTC

Acquisitions, Mergers, Takeovers

Infineon: Business Expected to Generate Rev of $225M-$250M in Calendar Yr 2025 With Gross Margin of Around 60% >IFX.FF

7 kwi 2025, 21:32 UTC

Acquisitions, Mergers, Takeovers

Infineon: Enters Agreement for Acquisition of Marvell Technology's Automotive Ethernet Business for US$2.5 B >IFX.FF

7 kwi 2025, 21:31 UTC

Top News

Apple Plans to Source More iPhones From India as Potential Tariff Fix -- Update

7 kwi 2025, 21:29 UTC

Top News

PNC Names Former BlackRock Star Mark Wiedman as President -- WSJ

7 kwi 2025, 21:28 UTC

Acquisitions, Mergers, Takeovers

Infineon Further Strengthens Its Number One Position In Automotive Microcontrollers And Boosts Systems Capabilities For Software-defined Vehicles With Acquisition Of Marvell's Automotive Ethernet Business >IFNNY MRVL

7 kwi 2025, 21:21 UTC

Top News

Defense Stocks Can't Escape the Trade War. Expect to Hear This Term. -- Barrons.com

7 kwi 2025, 21:18 UTC

Top News
Earnings

Levi Strauss Trying to Mitigate Tariff Impact on Consumer; Company Grows Revenue -- Update

7 kwi 2025, 21:17 UTC

Earnings

Levi Sees U.S. Consumer 'Generally Resilient,' CFO Says

7 kwi 2025, 21:17 UTC

Earnings

Levi Looking at Cost-Related Opportunities, Pricing Changes as Part of Response, CFO Says

7 kwi 2025, 21:16 UTC

Earnings

Levi Strauss Sets Up Task Force to Understand Implications of Trump's Tariffs, CFO Singh Says

7 kwi 2025, 21:16 UTC

Top News

What to Know About Trump's Latest Tariffs -- 3rd Update

7 kwi 2025, 21:15 UTC

Acquisitions, Mergers, Takeovers

Marvell to Sell In-Vehicle Network Portfolio for $2.5B

7 kwi 2025, 21:14 UTC

Top News

PNC Taps Ex-BlackRock Star Mark Wiedman as President -- WSJ

7 kwi 2025, 21:06 UTC

Top News
Acquisitions, Mergers, Takeovers

Trump Orders New Review of Nippon-U.S. Steel Merger -- 3rd Update

7 kwi 2025, 21:03 UTC

Top News

Even Google Could Feel the Sting of a Trade War -- Barrons.com

7 kwi 2025, 20:59 UTC

Top News

U.S. Stock Meltdown Gives Way to Global Rout -- WSJ

7 kwi 2025, 20:56 UTC

Major Market Movers

Broadcom Authorizes $10B Share Repurchase Program

Peer Comparison

Price change

Innoviva Inc Forecast

Price Target

By TipRanks

214.11% upside

12 Months Forecast

Average 55 USD  214.11%

High 55 USD

Low 55 USD

Based on 1 Wall Street analysts offering 12 month price targets forInnoviva Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

1 ratings

1

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

17.23 / 18.18Support & Resistance

Short Term

Bearish Evidence

Intermediate Term

Bearish Evidence

Long Term

Weak Bearish Evidence

Sentiment

By Acuity

359 / 386 Ranking in Healthcare

News Sentiment

Bearish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Innoviva Inc

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.